Part D
Part D
Ensuring a Robust Medicare Drug Benefit
Schaeffer researchers study Part D’s impact on formulary and benefit design, patient costs, innovation and overall health, with a focus on ensuring Medicare beneficiaries can access the high-value medications they need.
Related Topics
Top Stories View All
Perspective
Alzheimer’s Drugs Deserve a Second Opinion
Featured Experts: Paul Aisen, Joseph Grogan
In The News View All
Axios
A recent historic drop in drug prices is largely driven by market forces, Joyce explains
Featured Experts: Geoffrey Joyce
Morning Brew
Qato discusses how new PBM reforms may protect pharmacies and patient access
Featured Experts: Dima M. Qato
Tradeoffs
Trish interviewed on rising Medicare drug plan costs and narrowing options
Featured Experts: Erin Trish
The Hill
CMS staffing shortages could make the Medicare enrollment season challenging for beneficiaries, Blum warns
STAT
Joyce explains why Trump could more easily use Medicare negotiations, rather than most-favored nation, to slash drug prices
Featured Experts: Geoffrey Joyce
Featured Research
Reforming the Medicare Part D Benefit Design: Financial Implications for Beneficiaries, Private Plans, Drug Manufacturers, and the Federal Government
Researchers evaluate prescription drug claims from Medicare Part D beneficiaries to evaluate the current spending distribution.
Experts: Erin Trish, Geoffrey Joyce
